Recent News

• 06.11.2025 - Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus
• 06.11.2025 - Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus
• 06.05.2025 - Jefferies Global Healthcare Conference
• 06.05.2025 - Jefferies Global Healthcare Conference
• 05.27.2025 - Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
• 05.27.2025 - Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
• 05.22.2025 - Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting
• 05.22.2025 - Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting
• 05.12.2025 - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025
• 05.12.2025 - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025

Recent Filings

• 05.14.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 05.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.12.2025 - EX-99.1 EX-99.1
• 05.12.2025 - 8-K Current report
• 04.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors